The PDE4 inhibitor roflumilast is a clinically approved anti-inflammatory drug used for the treatment of chronic obstructive pulmonary disease. In addition, roflumilast was found to reduce body weight and improve glucose metabolism by a yet unknown mechanism.

Möllmann, J., Kahles, F., Lebherz, C., Kappel, B.a., Baeck, C., Tacke, F., et al. (2017). The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. DIABETES, OBESITY AND METABOLISM, 19(4), 496-508 [10.1111/dom.12839].

The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism

KAPPEL, BEN ARPAD;FEDERICI, MASSIMO;
2017

Abstract

The PDE4 inhibitor roflumilast is a clinically approved anti-inflammatory drug used for the treatment of chronic obstructive pulmonary disease. In addition, roflumilast was found to reduce body weight and improve glucose metabolism by a yet unknown mechanism.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
English
energy expenditure; glucose metabolism; hepatic steatosis; insulin resistance; mitochondria
Möllmann, J., Kahles, F., Lebherz, C., Kappel, B.a., Baeck, C., Tacke, F., et al. (2017). The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. DIABETES, OBESITY AND METABOLISM, 19(4), 496-508 [10.1111/dom.12839].
Möllmann, J; Kahles, F; Lebherz, C; Kappel, Ba; Baeck, C; Tacke, F; Werner, C; Federici, M; Marx, N; Lehrke, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/171418
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact